Goldman Sachs
TAK icon

Goldman Sachs’s Takeda Pharmaceutical TAK Stock Holding History

Goldman Sachs’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104M Buy
5,618,728
+813,493
+17% +$14.3M 0.01% 1000
2025
Q4 		$74.9M Sell
4,805,235
-148,096
-3% -$2.12M 0.01% 1192
2025
Q3 		$72.5M Buy
4,953,331
+452,366
+10% +$6.72M 0.01% 1148
2025
Q2 		$69.6M Sell
4,500,965
-819,828
-15% -$12.1M 0.01% 1121
2025
Q1 		$79.1M Buy
5,320,793
+692,404
+15% +$9.7M 0.01% 914
2024
Q4 		$61.3M Buy
4,628,389
+67,582
+1% +$928K 0.01% 1126
2024
Q3 		$64.9M Buy
4,560,807
+843,350
+23% +$12M 0.01% 1054
2024
Q2 		$48.1M Sell
3,717,457
-491,974
-12% -$6.51M 0.01% 1181
2024
Q1 		$58.5M Sell
4,209,431
-93,131
-2% -$1.35M 0.01% 1064
2023
Q4 		$61.4M Sell
4,302,562
-547,250
-11% -$7.76M 0.01% 1043
2023
Q3 		$75M Buy
4,849,812
+118,088
+2% +$1.83M 0.02% 861
2023
Q2 		$74.3M Buy
4,731,724
+380,221
+9% +$6.23M 0.02% 856
2023
Q1 		$71.7M Buy
4,351,503
+396,999
+10% +$6.32M 0.02% 832
2022
Q4 		$61.7M Sell
3,954,504
-317,965
-7% -$4.44M 0.02% 1008
2022
Q3 		$55.4M Buy
4,272,469
+637,688
+18% +$8.87M 0.01% 1045
2022
Q2 		$51M Sell
3,634,781
-607,908
-14% -$8.68M 0.01% 1115
2022
Q1 		$60.8M Buy
4,242,689
+509,886
+14% +$7.49M 0.01% 1121
2021
Q4 		$50.9M Buy
3,732,803
+1,198,284
+47% +$16.8M 0.01% 1325
2021
Q3 		$41.5M Buy
2,534,519
+712,636
+39% +$12M 0.01% 1418
2021
Q2 		$30.7M Buy
1,821,883
+207,183
+13% +$3.53M 0.01% 1683
2021
Q1 		$29.5M Buy
1,614,700
+16,751
+1% +$301K 0.01% 1602
2020
Q4 		$29.1M Sell
1,597,949
-90,197
-5% -$1.58M 0.01% 1546
2020
Q3 		$30.1M Buy
1,688,146
+661,886
+64% +$12.1M 0.01% 1408
2020
Q2 		$18.4M Buy
1,026,260
+267,379
+35% +$4.8M 0.01% 1746
2020
Q1 		$11.5M Sell
758,881
-1,224,908
-62% -$22.2M ﹤0.01% 1981
2019
Q4 		$39.1M Sell
1,983,789
-75,670
-4% -$1.45M 0.01% 1332
2019
Q3 		$35.4M Buy
2,059,459
+1,537,148
+294% +$26.6M 0.01% 1347
2019
Q2 		$9.24M Sell
522,311
-2,241,659
-81% -$40.8M ﹤0.01% 2416
2019
Q1 		$56.3M Sell
2,763,970
-2,339,649
-46% -$47.1M 0.02% 1020
2018
Q4 		$85.8M Buy
+5,103,619
New +$86.2M 0.03% 695

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs's TAK Position: Q1 2026 in Review

Goldman Sachs increased its Takeda Pharmaceutical (TAK) stake by 17% in Q1 2026, buying an estimated $14.3M and bringing the position to 5,618,728 shares worth $104M. The position accounts for 0.01% of the portfolio, ranked #1000.

Goldman Sachs first reported a position in TAK in Q4 2018 and has held it in 30 quarters since. 358 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Goldman Sachs held 5,618,728 shares of Takeda Pharmaceutical worth $104M as of Q1 2026.
  • Goldman Sachs bought 813,493 Takeda Pharmaceutical shares in Q1 2026, an estimated $14.3M.
  • Takeda Pharmaceutical made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1000 holding.
  • Goldman Sachs first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 30 quarters since.
  • 358 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.